HBV Genotyping Array for Drug Resistance Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiviral therapies for hepatitis B virus (HBV) face challenges such as the emergence of resistant mutant strains, which can lead to treatment failure and increased risk of hepatocellular carcinoma, and existing diagnostic methods are limited in detecting multiple mutations and genotypes simultaneously.
Innovation Solution
A comprehensive HBV array that allows for the simultaneous analysis of HBV genotypes, precore/core mutations, and polymerase gene mutations, enabling rapid and accurate detection of viral mutants and genotypes in patient serum samples, including those resistant to nucleoside/nucleotide analogues, using methods like ARMS-PCR and allele-specific primer extension.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If long-term treatment with nucleoside/nucleotide analogues is administered, then HBV DNA synthesis is inhibited, but resistant mutant HBV strains emerge
Solution Approach 1:
The patent applies preliminary action by performing genotyping and resistance mutation detection before initiating antiviral therapy. This allows clinicians to select appropriate first-line agents that the patient's virus is not resistant to, preventing the emergence of resistance before treatment begins. The detection methods identify pre-existing resistant strains or genetic predispositions to resistance, enabling proactive treatment selection rather than reactive adjustments after resistance develops.
Solution Approach 2:
The patent implements feedback mechanisms through monitoring systems that detect resistance mutations during long-term therapy. By regularly testing for resistance-associated mutations in the polymerase gene, the system provides feedback on treatment efficacy and viral adaptation. This enables clinicians to adjust treatment regimens based on detected resistance patterns, switching to alternative agents or combination therapies when resistance emerges, thus maintaining treatment effectiveness over time.
2Measurement precision
If multiple separate diagnostic tests are used to detect different HBV mutations and genotypes, then detection coverage is comprehensive, but testing time and complexity increase
Solution Approach 1:
The patent merges multiple separate diagnostic functions into a single integrated genotyping system. The methodology combines detection of HBV genotype, resistance-associated mutations in the polymerase gene, and susceptibility profile assessment into one unified test. This consolidation maintains comprehensive detection coverage while significantly reducing testing time from multiple separate assays to a single multiplex reaction, and simplifies the workflow from multiple testing steps to one integrated process.
Solution Approach 2:
The patent creates a universal diagnostic platform that performs multiple functions simultaneously. The single test system universally detects various HBV genotypes, identifies resistance mutations across different nucleoside/nucleotide analogues, and provides susceptibility predictions for multiple antiviral agents. This multi-functional approach eliminates the need for separate specialized tests for each detection target, reducing overall testing time while maintaining comprehensive diagnostic capability.
Data Source
AI summary
The present invention is a diagnostic kit and materials for: 1) the prediction of the long-term response of a chronic hepatitis B virus (HBV) carrier to treatment with nucleoside/nucleotide analog, or their combination; 2) the detection of HBV variants that exhibit reduced reactivity to antibody detection; 3) the detection of HBV variants in the precore/core region that negatively affect the course of liver disease; 4) the identification of the HBV genotype.